A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
Phase 3
55
about 1.6 years
10–17
41 sites in AR, AZ, CA +23
What this study is about
Researchers are testing different doses of dulaglutide in children with type 2 diabetes. The trial will last about 8 months.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Dulaglutide
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
dulaglutide
Primary: Number of Participants with One or More Serious Adverse Events (SAE) Considered by the Investigator to be Related to Study Drug Administration
Secondary: Change from Baseline in Hemoglobin A1c (HbA1c), Change from Baseline in Total Cholesterol, Change from Baseline in the EQ-5D-Y-5L, PK: Maximum Observed Concentration (Cmax) of Dulaglutide, Percent Change from Baseline in Body Weight, Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of Dulaglutide
Endocrinology